Lipdaune

Lovastatin, the active ingredient in Lipdaune, is a HMG‑CoA reductase inhibitor presented as an oral tablet for oral use. It lowers elevated cholesterol levels and is indicated for patients with hypercholesterolemia, familial hypercholesterolemia, and for the primary prevention of cardiovascular disease.

GNH USA supplies Lipdaune as a licensed, GDP‑compliant international pharmaceutical product serving hospitals, pharmacies, clinics and procurement teams worldwide, adhering to EU quality standards and export regulations. The company provides regulatory support, cold‑chain logistics where required, and reliable lead times for global markets.

Lovastatin is used to manage disorders of lipid metabolism and to reduce cardiovascular risk. - Hypercholesterolemia: lowers total cholesterol and low‑density lipoprotein (LDL‑C) concentrations, supporting achievement of guideline‑recommended lipid targets. - Familial hypercholesterolemia: reduces markedly elevated LDL‑C levels in patients with inherited cholesterol metabolism defects, complementing diet and lifestyle measures. - Prevention of cardiovascular disease: improves lipid profile to diminish the incidence of myocardial infarction, stroke and related atherosclerotic events in at‑risk individuals.

Lovastatin may be associated with a range of adverse reactions, most of which are mild and reversible. Common Side Effects: - Headache: mild to moderate pain in the head region. - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia. - Muscle aches: mild myalgia without weakness. - Elevated liver enzymes: transient increase in ALT/AST. Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown that can lead to renal failure. - Hepatotoxicity: significant elevation of liver enzymes or hepatitis. - Severe allergic reaction: rash, angioedema or anaphylaxis.

When prescribing Lovastatin, clinicians should consider several safety and handling precautions to minimize risk. - Liver function monitoring: assess baseline ALT/AST and repeat periodically. - Muscle toxicity vigilance: educate patients to report unexplained muscle pain or weakness. - Drug interactions review: avoid concomitant use with strong CYP3A4 inhibitors. - Pregnancy contraindication: do not prescribe to pregnant women (Category X). - Renal impairment adjustment: use caution in patients with severe renal dysfunction. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture.

Lovastatin interacts with several medicines that can alter its plasma concentration or increase toxicity. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): can cause marked increase in Lovastatin levels and risk of rhabdomyolysis. - Gemfibrozil: synergistic effect on muscle toxicity, may lead to severe myopathy. Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce absorption, decreasing efficacy. - Warfarin: Lovastatin may enhance anticoagulant effect; monitor INR. - Grapefruit juice: can increase Lovastatin exposure modestly; advise limited intake.